---
title: "SHAREATE released its 2024 annual performance, with a net profit attributable to the parent company of 181 million yuan, a year-on-year increase of 10.89%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236408522.md"
description: "SHAREATE released its 2024 annual performance, with operating revenue of 1.862 billion yuan, a year-on-year increase of 20.17%; net profit attributable to the parent company of 181 million yuan, a year-on-year increase of 10.89%; net profit excluding non-recurring gains and losses of 157 million yuan, a year-on-year increase of 14.02%; basic earnings per share of 1.01 yuan/share. The company plans to distribute a cash dividend of 3 yuan (tax included) for every 10 shares and to increase capital by issuing 4 additional shares for every 10 shares to all shareholders"
datetime: "2025-04-17T11:36:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236408522.md)
  - [en](https://longbridge.com/en/news/236408522.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236408522.md)
generator: "portal-rs"
---

# SHAREATE released its 2024 annual performance, with a net profit attributable to the parent company of 181 million yuan, a year-on-year increase of 10.89%

According to the Zhitong Finance APP, SHAREATE (688257.SH) released its annual report for 2024, reporting an operating income of 1.862 billion yuan for the year, a year-on-year increase of 20.17%; a net profit attributable to shareholders of the listed company of 181 million yuan, a year-on-year increase of 10.89%; a net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of 157 million yuan, a year-on-year increase of 14.02%; and basic earnings per share of 1.01 yuan/share. It plans to distribute a cash dividend of 3 yuan (including tax) for every 10 shares and to increase the capital reserve by converting 4 shares for every 10 shares to all shareholders

### Related Stocks

- [688257.CN](https://longbridge.com/en/quote/688257.CN.md)

## Related News & Research

- [BioGaia (OM:BIOG B) Could Be 26% Undervalued Following Its Recordati Deal](https://longbridge.com/en/news/298111133.md)
- [GIGADEVICE Forecasts Tight DRAM Supply Situation to See No Noticeable Relief Next Yr](https://longbridge.com/en/news/297725585.md)
- [US, allies want IAEA board to report Iran to UN Security Council, diplomats say](https://longbridge.com/en/news/298047993.md)
- [Egetis says new Emcitate clinical data from Triac Trial II, ReTRIACt to be presented at September congresses](https://longbridge.com/en/news/297996002.md)
- [Tezos to Launch Post-Quantum Testnet in September](https://longbridge.com/en/news/297946567.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**